Amman, Dec. 19 (Petra) -- Hikma Pharmaceuticals PLC (LSE: HIK) (Hikma), a global pharmaceutical company, has entered into a definitive agreement with Takeda Pharmaceuticals International AG to acquire the rights to 17 established brands across the Middle East and North Africa (MENA) region.

The acquisition encompasses a portfolio of market-leading products in key therapeutic areas including cardiovascular, diabetes, gastroenterology, and pain management.

These products were previously licensed to Hikma through various agreements, with the most recent partnership established in 2017.

Under the terms of the agreement, Hikma will gain full rights to the portfolio and plans to transition manufacturing operations in-house, ensuring sustainable supply chain control and operational efficiency. This strategic move is expected to generate significant cost synergies and enhance the profitability of Hikma's Branded business segment.

"This acquisition represents a natural evolution of our long-standing partnership with Takeda and reinforces our position as a leading pharmaceutical company in the MENA region," said Mazen Darwazah, Executive Vice Chairman and President of MENA at Hikma.

"By integrating these established products into our manufacturing network, we can optimize our operations while ensuring reliable access to essential medicines for patients across our markets."
The portfolio acquisition aligns with Hikma's strategic focus on expanding its branded pharmaceutical presence in MENA, where the company maintains extensive commercial infrastructure and deep market expertise.

The transition will leverage Hikma's established sales and marketing capabilities, which have successfully commercialized these products throughout the region.
Financial terms of the transaction were not disclosed. The acquisition remains subject to customary closing conditions and regulatory approvals.

//Petra// AA

19/12/2024 10:36:41